Amyvid
(Florbetapir F 18)ApprovedSmall molecule
Florbetapir F 18 is used in PET imaging scans to help detect amyloid plaques in the brains of people being evaluated for memory problems or cognitive decline, which can indicate Alzheimer's disease.[2] Amyvid is currently approved and in use across 6 indications[4].[1]
Amyvid is one of 206 small molecule programs targeting Cognitive impairment. It is currently in Approved.
6
Indications
24
Total Trials
1
Active Trials
205
Competitors
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
279 competitors in Cognitive Impairment
#DrugCompanyPhaseTrials
1Amyvid
AAvid Radiopharmaceuticals
Approved
Actos
TakedaPhase 3
Farxiga
AstraZenecaPhase 3
Provigil
NNuvo Research GmbH
Phase 3
Xarelto
WWim Janssens
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Viagra
VViatris Specialty LLC
Phase 3
Donepezil Hydrochloride
EisaiPhase 3
Statins
SanofiPhase 3
Galantamine Hydrobromide
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cognitive impairment3 trials
Alzheimer's Disease3 trials
AIN3 trials
Imaging2 trials
11 more indications
Parkinson's Disease1 trial
Alzheimer's Disease (AD)1 trial
Observational Study1 trial
MPA1 trial
Encephalopathy1 trial
Cognitive Decline1 trial
Phase II1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Amyvid drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Florbetapir F 18. EMBL-EBI & Wellcome Sanger Institute.
- [5]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- AAvid Radiopharmaceuticals